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Experimental Intestinal Transplantation 
Fifty years after Alex Carrel performed the first attempts at canine intestinal 
transplantation in 1902,1 two major works were carried out independently 
at the University of Minnesota and Northwestern University. In 1959, Lille-
hei et al. 2 reported a technique for isolated intestinal transplantation in 
dogs. Lillehei and co-workers removed the entire small bowel, except for 
short segments at the proximal jejunum and distal ileum, on a vascular 
pedicle of the superior mesenteric artery and the superior mesenteric vein. 
The graft was immersed in cold normal saline and transplanted orthotopi-
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cally into the same dog or a companion animaL In 1960, Starzl and 
Kaupp3 described a multivisceral transplantation in dogs, a technique to 
transplant the small bowel as a composite of abdominal organs. The grafts 
included the stomach, liver, pancreas, intestine, and colon. Two central ar-
teries, the celiac axis and the superior mesenteric artery in continuity with 
the aorta, were joined to the recipient infrarenal aorta. Both experiments 
clearly demonstrated the technical feasibility of intestinal transplantation, 
and became the standard method currently used for composite (either 
multivisceral or small bowel and liver) grafting or for isolated small-bowel 
grafting in intestinal transplantation. These two studies, along with a small 
animal experiment by Monchik and Russell,4 paved the way for investigat-
ing the problems related to this procedure, such as immunology, immuno-
suppression, graft preservation, metabolic events, and graft function. 
Clinical Intestinal Transplantation 
Although the intestine was one of the first organs to be transplanted ex-
perimentally, clinical intestinal transplantation had been unsuccessful until 
recently, primarily owing to the absence of potent immunosuppressive 
agents. 
Before cyclosporine was introduced, seven unsuccessful intestinal trans-
plants were performed5 - 9; the longest patient sUrvival was 76 days.9 
These patients had no other therapeutic option since total parenteral nutri-
tion (TPN) had not yet been developed. Azathioprine, steroids, antilym-
phocyte globulin (ALG), or thoracic duct drainage were used for immuno-
suppressive therapy, but the patients died from rejection, as well as poor 
graft preservation, technical complications, and sepsis. 
The development of TPN in the early 1970s, combined with the con-
secutive failures at transplanting the intestine, inhibited the development of 
clinical intestinal transplantation for almost a decade. However, the lull 
ended when Cohen et aL,lO at the University of Toronto in 1986, per-
formed the first intestinal transplantation using cyclosporine. The patient 
survived for only 10 days. 
Extended survival of an intestinal transplant recipient was first accom-
plished in 1987,11 when a 31/z-year-old girl lived for 192 days after receiv-
ing a multiorgan transplant for short-gut syndrome and TPN-induced liver 
failure. Postoperative immunosuppression was with cyclosporine, steroids, 
OKT3, and irradiation. The intestinal graft, as well as the other organ al-
lografts, was fully functional for almost 6 months until she died of postop-
erative lymphoproliferative disease. There was no histologiC evidence of 
graft rejection at autopsy. The following year Grant and co-workers1Z per-
formed a successful combined intestine and liver transplant in London, 
Ontario. The patient was a 41-year-old woman who lost her small bowel 
as a result of superior mesenteric artery thrombosis caused by antithrom-
bin III deficiency. Mild episodes of graft-vs.-host disease (GVHD) and re-
jection developed during the early postoperative period but were easily re-
versed by therapy. To date, this patient and a second patient13 who re-
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ceived the same procedure by Grant's group are alive and doing well, with 
functioning grafts. 
Experience with isolated small-bowel transplantation under cyclosporine 
has been unsatisfactory when compared to the experience in liver and in-
testinal transplantation. Including the case of Cohen et al.,l0 a total of 13 
isolated intestinal transplants were reported from centers in Chicago (n = 
1),14 Paris (n = 7),15 Kiel, Germany (n = 2),16. 17 London, Ontario (n = 
1),18 and Uppsala, Sweden (n = 1),19 of which 11 grafts were lost. Only 
two fcatients receiving grafts from living-related donors17 or cadaver do-
nors 0 are currently alive with functioning grafts, a success rate of 15%. 
Recent statistics from the International Small Bowel Transplantation Regis-
try (Dr. D. Grant, personal communication, December 1992) show that 
the survival rate after isolated grafting and combined grafting was 6% (11 
15) and 75% (3/4), respectively. Grant attributes the more favorable out-
come of combined transplantation compared to isolated grafting to a pro-
tective or tolerogenic effect by the liver over the intestinal graft, a concept 
which was first indicated by Starzl in his multiorgan tranwlantation experi-
ment, and later confirmed and extended by Caine et al. 1 and Kamada et 
al. 22 
The advent of a new immunosuppressive agent, FK506, appears to 
have transformed intestinal transplantation from experimental to practical 
reality. 23, 24 Although the chemical structure and binding immunophilin 
are different from cyclosporine, FK506 has a similar but more potent im-
munosuppressive action than cyclosporine. Nephrotoxic, neurotoxic, and 
diabetogeniC side effects of the two drugs are Similar, but FK506 causes no 
gingival hyperplasia or hirsutism. Encouraged by the results of experimen-
tal intestinal tran~lantationORI 26 as well as the results of clinical solid organ 
transplantations2 under FK506, we initiated a cljnical trial of intestinal 
transplantation in May 1990. From that time through November 1992, a 
total of 30 patients received either isolated intestinal transplantation (n = 
9), combined intestinal and liver transplantation (n = 17), or multivisceral 
transplantation (n = 4). Of these recipients, 24 are currently alive with 
functioning grafts on unrestricted oral diets after a minimum follow-up of 4 
months. 
Indications 
Intestinal Failure 
Intestinal failure is defined as a state of inability to maintain nutrition or 
positive fluid and electrolyte balance without special support owing to the 
loss of absorptive surface or function of the native small bowel. 28 
Normally, an adult ingests 2 L of fluid daily, and produces 7 to 8 L of 
fluids as gastric, biliary, pancreatic, and intestinal secretions, of which only 
100 to 200 mL of fluid is expelled with feces. The intestine has an enor-
mous capacity to absorb water as well as nutrients, electrolytes, vitamins, 
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minerals, and substances that recirculate via the enteric route. If absorptive 
function or the intestinal surface area is excessively lost, malnutrition, de-
hydration, metabolic abnormalities, sepsis, and mortality are the sequelae 
of events, unless management with TPN takes place. Currently, most pa-
tients receive TPN at home, as home parenteral nutrition (HPN). From 
Medicare data, approximately 19,700 patients, or 80 per million, were on 
HPN in the United States in 198729; this figure is much higher than the 2 
to 4 per million in Europe because of more liberal use of the therapy in the 
United States. 28 
Causes of Intestinal Failure 
Causes of intestinal failure can be classified into two categories: (1) failure 
due to surgical or anatomic loss, or (2) failure due to functional abnormal-
ity. Surgical intestinal failure (short-bowel syndrome) may occur after ma-
jor resection of the intestine for such indications as congenital anomaly, 
vascular thrombosis, volvulus, necrotizing enterocolitis, inflammatory 
bowel disease, trauma, and desmoid tumor. Functional intestinal failure is 
caused by either an enterocyte abnormality or by intestinal dysmotility. Mi-
crovillus inclusion disease and radiation enteritis are examples of an en-
terocyte abnormality. Functional intestinal failure due to motility disorder 
(intestinal pseudo-obstruction) is caused by either a myopathy or neuropa-
thy of the intestinal wall. Table 1 summarizes the cause of intestinal failure 
for the 204 patients who were referred to our center for evaluation for in-
testinal transplantation from 1990 through 1992. 
TABLE 1. 
Cause of Intestinal Failure for Patients Referred to the 
Pittsburgh Transplantation Center 
Adults Children 
Indication No. Indication 
Crohn's disease 22 Necrotizing enterocolitis 
Thrombotic disorder 22 Gastroschisis 
Trauma 12 Volvulus 
Pseudo-obstruction 11 Pseudo-obstruction 
Radiation enteritis 5 Intestinal atresia 
Familial polyposis 4 Hirschsprung's disease 
Volvulus 4 Megacystic colon 
Budd-Chiari syndrome 2 Microvillus inclusion 
disease 
Desmoid tumor 2 Malrotation 
Gardner's syndrome 2 Other 
Other 19 
No. 
25 
19 
14 
10 
6 
3 
3 
3 
2 
14 
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Intestinal Adaptation 
After massive enteric resection, the residual bowel is known to undergo 
adaptive changes to compensate for the loss of absorptive surface area by 
widening the circumference and increasing the villus height. 30 Intraluminal 
nutrients, pancreatobiliary secretions, hormones, and enterotrophic factors 
facilitate the adaptation process. Clinically, the adaptive process has been 
divided into stages: stage I at 7 to 10 days, when massive diarrhea impels 
intensive repletion of fluid and electrolyte losses; stage II at 1 to 3 months, 
when diarrhea stabilizes and full TPN support and other medical manage-
ment are required; and stage III at 3 to 12 months, when diarrhea is con-
trolled to institute enteral feeding and discontinue TPN. If TPN cannot be 
discontinued from 12 to 24 months after the initial insult, intestinal failure 
approaches an irreversible state, and most of the patients require TPN per-
manently. Typically, one half of the patients who are placed on TPN re-
quire fermanent therapy (1-2 per million with irreversible intestinal fail-
ure).2 
The irreversibility of surgical intestinal failure, although difficult to deter-
mine at the time of small bowel resection, correlates with the length of re-
maining bowel, the site of intestinal resection, and the presence or absence 
of the ileocecal valve. Willmore,31 in 1972, stated that the survival of in-
fants is highly unlikely if remaining bowel length is less than 40 cm and if 
the ileocecal valve is removed. More recently, patients with as little as 10 
cm of bowel length and an intact ileocecal valve have been reported32 to 
recover from intestinal failure. In general, resection of more than 80% of 
the small bowel, along with the ileocecal valve, are high-risk factors for 
permanent loss of intestinal absorptive function. Resection of the jejunum 
and retention of the ileum are favorable since the remaining ileum has ac-
tive adaptive capacity. The loss of the large bowel is also serious since the 
gastrOintestinal tract loses the ability to absorb water. 
Problems Associated with TPN 
Patients who are placed on TPN cannot escape the threat of TPN-related 
complications. Along with problems that occur at the time of catheteriza-
tion, long-term TPN management is beset by various complications and 
frequent hospital admissions for care. These complications include vascular 
thrombOSiS, metabolic abnormality, bone disease, cholelithiasis, and often 
lethal sepsis and liver disease. Of the 1,594 HPN patients followed by the 
OASIS registry since 1984, those with benign intestinal diseases experi-
enced 2.6 complications requiring hospitalization per year.29 Three-year 
survival ranged from 65% to 80% depending on the cause of disease, of 
which 6.7% of the deaths were from TPN-related complications. In Eu-
rope, sepsis, major vessel thrombosis, and liver failure are ascribed to 28% 
of the patient deaths under TPN therapy.33 
Liver disease induced by TPN is very serious, especially in infants. Cho-
lestasis usually appears in 30% to 40% of the patients under long-term 
TPN management, and sometimes progresses to Significant liver failure. 
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The analysis by Grosfeld et al. 34 of 60 infants showed that cholestasis was 
reversible if the patient was switched from TPN to complete enteral feeding 
and if the total bilirubin was less than 30 mg/dL. If the total bilirubin was 
greater than 30 mg/dL, reversal did not occur. Five of the nine deaths in 
Grosfeld's series were due to liver failure. The same trend was observed 
with pediatric patients who were referred to our center. Of the 99 pediatric 
patients referred to us (see Table 1), 25 died from liver failure and sepsis 
while awaiting intestinal transplantation. 
Social problems are another important issue related to long-term TPN 
therapy. Because of the limitations on social and personal activities, some 
TPN patients become very dependent on their caregiver, and sometimes 
experience psychiatric disturbances and drug abuse. The cost of TPN 
maintenance is very expensive, and increasing. In 1980, the cost per pa-
tient ranged from $16,506 to $24,939 per year, increased to $17,000 to 
$127,000 per year by 1983,35 and is currently estimated at $75,000 to 
$150,000 per year.29 
Types and Indications of Intestinal Transplantation 
Surgical procedures performed to correct short-bowel syndrome are not al-
ways successful. 36 Implantation of the intestine is therefore the theoretical 
and only reliable choice to cure patients who are at the irreversible stage of 
anatomic and functional intestinal failure. Currently, three different types of 
intestinal transplantation can be performed depending upon the cause and 
severity of intestinal failure and the presence of extraenteric organ dysfunc-
tion. 
Isolated intestinal transplantation is indicated for patients who have irre-
versible small-bowel failure with no other organ dysfunction. Since it is still 
at the experimental stage, at this time we perform this procedure in highly 
selected patients, such as those whose venous accesses are running out 
because of major vessel thrombosis or for Crohn's disease patients who 
are refractory to any conventional surgical and medical treatments. 
Transplantation of combined intestine and liver grafts is performed for 
patients who have intestinal failure and liver disease caused by TPN or in-
born error. Particularly, the patients who have very high bilirubin levels or 
recurrent variceal bleeding require transplantation urgently. Multiorgan 
transplantation is less frequent. It is reserved for patients who have severe 
dysmotility of the entire gastrOintestinal tract, occlusion of both the celiac 
axis and the superior mesenteric artery, thrombosis of the entire mesen-
teric venous system, or extensive polyposis throughout the digestive tract. 
Donors 
Selection of Donors 
Grafts for intestinal transplantation are obtained from cadaver donors. The 
general criteria for donor selection do not differ from those for liver donors. 
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Donors with stable cardiopulmonary status and liver function are suitable. 
Those with systemic infection and malignancy are excluded. ABO blood 
type should be identical between donor and recipient. HLA matching is 
not currently considered and is universally poor. Donors with prior cyto-
megalovirus (CMV) infection require special consideration, especially when 
recipients are negative for CMV. These recipients always develop severe 
and persistent CMV infection postoperatively despite aggressive prophy-
laxis and treatment. Donors who are of similar size as the recipients, or 
preferably one fourth to one third smaller, are recommended to avoid tight 
and difficult closure of the abdominal wound at transplantation. 
Theoretically, living-related donors can donate isolated intestinal grafts, a 
minimum of 60 em in adults,17 but this may not be justified except in cases 
of complete HLA matching between donor and recipient. Organ supply 
from cadaver donors, 4,000 to 4,500 annually in the United States, ex-
ceeds the estimated number of patients, 1 to 2 per million, or 200 to 
400,28 who will require permanent TPN. More important, isolated intesti-
nal transplantation can be delayed until the most suitable organ becomes 
available since it is not an urgent, lifesaving procedure. 
Donor Operation 
After the donor is accepted, selective decontamination of the gastrointesti-
nal tract is begun through a nasogastric tube (10-30 mLimin) using a 
polyethylene glycol-electrolyte solution (Golytely) containing amphoteri-
cin B 500 mg; tobramycin 80 mg; and polymixin E 100 mg. Intravenously, 
cefotaxim 25 mg/kg and ampicillin, 25 mg/kg are also administered. 
Immunomodulation of the graft using radiation, mesenteric lymph node 
dissection, or antilymphocyte antibody administration has been recom-
mended to lessen rejection episodes in many experimental studies, but 
without Significant benefit in clinical cases. 14 None of these procedures 
have been adopted with our patients. 
Logistics and steps of the donor operation were described else-
where.37, 38 Briefly, the abdomen is opened through a thoracoabdominal 
incision. For procurement of an isolated graft, the whole small bowel and 
the ascending and transverse colon are mobilized by dividing retroperito-
neal fusions. The terminal ileum adjacent to the ileocecal valve is stapled 
and divided, and vessels within the ascending and transverse mesocolon 
are divided. When the middle colic vessels are diVided, the superior mes-
enteric artery and vein are exposed at the inferior border of the pancreas. 
The proximal jejunum is stapled and transected close to the ligament of 
Treitz. Dissection of the superior mesenteric vein is extended to its conflu-
ence with the splenic vein. Transection of the pylorus and the neck of the 
pancreas facilitates exposure of both vessels and the portal vein. The supe-
rior mesenteric artery is dissected to the root at the anterior surface of the 
abdominal aorta. Care must be taken to preserve the right hepatic artery 
from the superior mesenteric artery if it is found. 
When the intestine is procured with the liver, hepatic hilar dissection, as 
usually done in harvesting the liver graft, is performed initially. The distal 
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common bile duct is transected. The hepatic artery is dissected to the ori-
gin of the celiac axis by dividing the gastroduodenal artery, splenic artery, 
and left gastric artery. After the intestine is isolated, the portal vein is com-
pletely isolated by dividing tributaries draining into the portal vein carefully 
to procure both organs in continuity with the portal vein. Multivisceral pro-
curement follows the hepatic hilar dissection, intestinal isolation, and dis-
section of the left upper abdominal organs (stomach, pancreas, and 
spleen), in that order. After the intestine is isolated, the pancreas and 
spleen are mobilized from the retroperitoneum, and the abdominal 
esophagus is stapled and transected a few centimeters proximal to the 
esophagogastric junction. The celiac axis and the superior mesenteric ar-
tery are resected together as a Carrel patch without injuring the origins of 
the renal arteries. Procurement of both donor iliac artery and vein, and the 
thoracic aorta are mandatory for vascular reconstruction at transplantation. 
Preservation of the Graft 
After systemic heparinization, the intestine and other abdominal organs are 
flushed with 1 to 2 L of chilled University of Wisconsin (UW) solution via a 
catheter inserted into the lower abdominal aorta. When the liver is har-
vested with the intestine, an additional 1 L of UW solution is given, in situ 
or on the back table, into the liver through the inferior mesenteric vein. 
Care needs to be taken to minimize the amount of UW solution used for 
intestinal perfusion to avoid swelling of tissues. Although luminal flushing 
with an electrolyte solution containing antibiotics is common practice in the 
other center,15 it was omitted with our patients to simplify the procedure 
and to avoid bacterial contamination. The graft is stored on ice for trans-
port. Preservation time varies from 2.8 to 11.1 hours, with a mean of 7.7 
hours. 
Similar to the transplantation of other solid organs, an effective method 
to maintain better graft viability during preservation is a key to success in 
intestinal transplantation. Simple cold storage with UW solution39 has been 
used for this purpose in all of our cases except for one, where an isolated 
intestinal graft was excised and simply immersed in cold lactated Ringer's 
solution. Although no postoperative problems were seen in any of these 
cases, it has not yet been determined whether UW solution is the most ap-
propriate preservation solution for intestinal preservation. Better animal 
survival and motility function have been shown in rat intestinal grafts pre-
served with UW solution,40 but ener~y stores were inferior to the grafts 
preserved with Euro-Collins solution.4 Additionally, UW-preserved canine 
small bowel showed more lipid peroxidation damage when compared to 
Euro-Collins-preserved grafts. 42 
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Recipients 
Evaluation of the Recipient 
Hematologic studies, infectious status, hepatic and renal function, cardio-
pulmonary status, and immunologic studies are performed as is routine 
with most of the solid organ recipients. The nature and course of intestinal 
failure and the anatomic and functional status of the remaining gastrointes-
tinal tract are particularly important since the type of transplantation is de-
cided on these factors. Anatomic assessments include a detailed history of 
past surgery (frequency, reason, and type of operation), length and loca-
tion of remaining intestine, presence or absence of the ileocecal valve, and 
abnormality of the splanchnic vessels and major systemic vessels. Barium 
study, endoscopy, computed tomography (CT), ultrasound, and angiogra-
phy are used for anatomic assessment. Motility studies of the entire gastroi-
ntestinal tract, from the stomach to the rectum, are essential to determine 
the severity and extent of functional intestinal failure. Total gastric resection 
is considered if there is a marked gastric atony. If rectal function is normal 
and if lesions are confined only within the mucosal layer (e.g., multiple pol-
yposis), a pull-through technique using transplanted intestine may be 
added to gastrOintestinal reconstructions. If patients have evident liver fail-
ure, such as high bilirubin, cirrhOSiS, variceal bleeding, or splenomegaly, 
they are candidates for combined intestine and liver transplantation. How-
ever, if the liver damage is not advanced, accompanied only by mild fibro-
sis at the portal triad or a lower bilirubin level, isolated intestinal transplan-
tation is chosen. 
Finally, determination of absorptive function of the remaining intestine is 
important, since some intestinal failure patients who were referred to our 
center were able to be switched from TPN to enteral feeding to avoid in-
testinal transplantation. 
Recipient Operation 
Final judgment on the type of transplantation that will be performed is 
made after laparotomy by careful investigation of native vessels and ab-
dominal organs. Close and frequent communication between the donor 
team and the recipient surgeons is essential. 
The abdomen is opened through a midline incision with a unilateral or 
bilateral transverse incision. AIl of the adhesions from the multiple surgeries 
(if any) are carefully dissected. Figure 1 illustrates the methods of vascular 
and gastrOintestinal reconstruction for the three types of intestinal trans-
plantation. For arterial reconstruction, the anterior wall of the recipient in-
frarenal aorta is used exclUSively for end-to-side anastomosis with the su-
perior mesenteric artery in isolated intestinal grafting, or with a Carrel 
patch containing both the celiac axis and the superior mesenteric artery for 
combined intestinal and multivisceral grafting. Venous outflow from the 
isolated small-bowel graft is drained into the recipient mesenteric venous 
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A B 
FIG 1. 
Intestinal transplantation. A, isolated grafting; S, combined intestine and liver graft-
ing; C, multivisceral grafting. PV = portal vein; SMV = superior mesenteric vein; 
SMA = superior mesenteric artery; IVe = inferior vena cava. (From Todo S, Tza-
kis A, Abu-Elmagd K, et al: Ann Surg 1992; 216:223-234. Used by permission.) 
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system (rather than into the vena cava) either by anastomosing the donor 
superior mesenteric vein to the distal end of the recipient superior mesen-
teric vein, to the confluence of the superior mesenteric vein with the 
splenic vein, or to the main trunk of the portal vein at the hepatic hilum 
(mesenteric piggyback technique).43 Mesocaval anastomosis was required 
only on one occasion for the retransplantation of an isolated graft. In one 
combined intestine and liver transplant, a portacaval shunt was created be-
fore the native hepatectomy. This decreases venous congestion in the re-
maining organs and bleeding during the procedure. Venovenous bypass, 
used in orthotopic liver transplantation, is not applicable in most cases be-
cause of the thromboses of major vessels from TPN. After the liver is re-
placed by the piggyback method,44 the portacaval shunt is converted to a 
porta portal shunt by anastomosing the recipient portal vein to the side of 
the graft portal vein. This ensures that the transplanted liver is being per-
fused by the recipient splanchnic venous blood containing so-called hepa-
totrophic substances.45 If the recipient portal vein is too short, or the graft 
portal vein is too small for anastomosis, a portacaval shunt can be left in 
place permanently. In multivisceral transplantation, removal of the native 
organs is performed in the same way as the donor operation, and the 
grafts are transplanted en bloc. 
Reconstruction of gastrointestinal continuity in isolated and combined 
grafting is achieved by joining each end of the intestinal graft to each of the 
remaining bowel ends. It is important to leave the recipient intestine as 
long as possible, since it will enable reanastomosis or enterostomy if the 
graft needs to be taken out later. Proximal intestinal reconstruction in mul-
tivisceral transplantation is achieved by anastomosing the distal esophagus 
to the anterior wall of the graft stomach, to which pyloroplasty is added 
routinely. Three enterostomies are necessary for intestinal transplantation. 
Gastrostomy is made to decompress intestinal congestion during the early 
postoperative period and to control delayed gastric emptying, which occurs 
postoperatively in most recipients. Jejunostomy is made for intestinal de-
compression and as a route for enteral feeding. The distal end of the graft 
is exteriorized by the chimney method, in which the recipient ileum or co-
lon is anastomosed to the side of the graft below the stoma. The stoma is 
used as a route for endoscopic examination and mucosal biopsy. Chole-
cystectomy is performed in all cases, and biliary reconstruction by chole-
dochojejunostomy is made in all combined graftings. 
Postoperative Management 
Immunosuppression 
Postoperative immunosuppression is by a combination of FK506, steroids, 
and prostaglandin El (PGE1, Prostin), starting immediately after graft 
reperfusion. FK506 is administered by continuous intravenous infusion at 
doses of 0.1 to 0.15 mg/kg/day, and continued for 7 to 10 days until pa-
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Immunosuppression of intestinal recipients. A, adult patients (n = 15); B (next 
page), pediatric patients (n = 15). Pred = prednisone; AZA = azathioprine. 
tients can tolerate enteral feeding. Intravenous FK506 is switched to oral 
formula at 0.3 mg/kg/day (divided doses) with several days of overlap. 
Since FK506 pharmacokinetics is influenced by intestinal function, hepatic 
abnormality, and other medications, it is important to measure drug levels 
frequently: daily during hospitalization, two to three times per week for 
several months, and weekly thereafter. Plasma trough levels of FK506 are 
maintained at 2 to 3 ng!mL, or slightly higher, for the first month, at 1 to 2 
ng!mL till the third month, and approximately at 1 ng/mL thereafter 
(Fig 2). 
Steroids, 1 g of methylprednisolone in adults, or hydrocortisone in chil-
dren, are given intraoperatively, followed by a steroid taper from 200 mg! 
day (adult) or 100 mg/day (pediatric) in decrements of 40 mg!day (adult) 
or 20 mg/day (pediatric) over the first 5 days. Baseline steroid doses of 20 
mg/day (adult) or 10 mg/day (pediatric) are gradually lowered over the 
next few months and maintained at 5 to 10 mg/kg/day, or discontinued. 
Continuous intravenous infusion of PGEI is essential to success in intes-
B 
3 
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tinal transplantation. It allows maintenance of higher FKS06 plasma levels, 
by protecting the kidney from FKS06 renal toxicity, and possible augmen-
tation of immunosuppression.46 Prostin is started at 0.2 J.1g/kg/hr, and 
gradually increased to 0.6 to 0.8 J.1g/kg/hr if recipient hemodynamics are 
stable. Prostin is continued until intravenous FKS06 is discontinued. 
In addition to these agents, azathioprine at doses of 0.5 to 1.0 mglkgl 
day is supplemented if the therapeutic FK506 dose is not maintained due 
to renal dysfunction, or if there is recurrent rejection. 
Monitoring and Treatment of Intestinal Rejection 
Although a number of functional and biochemical markers of intestinal re-
jection have been proposed in experimental transplantation models, al-
most all of them are not clinically practical. Intestinal rejection progresses 
very rapidly from mild to severe if it is not treated immediately. Early de-
tection of graft rejection is imperative. In our experience, a combination of 
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clinical observation, endoscopic examination, and histopathologic analyses 
of multiple endoscope-guided mucosal biopsies have been used to achieve 
this objective. If rejection of the intestinal graft is suspected clinically, the 
native and transplanted intestine is immediately and thoroughly examined 
with the endoscope and by histopathologic study. A choice of treatments is 
made, based exclUSively on the severity of graft rejection as determined by 
these investigations. Characteristic findings of mild, moderate, and severe 
intestinal rejection and their treatment is outlined in Table 2. 
Prevention of Infection 
The same kind of selective decontamination used in the donor is given to 
the recipient postoperatively, and continued for 4 to 6 weeks after trans-
plantation. Prevention of systemic infection is achieved by intravenous ad-
ministration of broad-spectrum antibiotics: ampicillin and cefotaxim, given 
for the first 5 days. Cultures of the blood, stool, urine, sputum, wound 
exudate, and stomal and peritoneal discharge are repeated frequently and 
proper antibiotic therapy is given accordingly. Gancyclovir, sulfamethox-
azole-trimethoprim (Bactrim), and nystatin (Mycostatin) are given for pro-
phylaxis of CMV, Pneumocystis cannii, and Candida infection, respec-
tively. 
Nutrition 
Total parenteral nutrition is restarted within 1 to 2 days after transplanta-
tion (when patients become hemodynamically stable). At 7 to 10 postop-
erative days, enteral feeding via a jejunostomy tube is begun after integrity 
and continuity of the gastrOintestinal (GIl tract is confirmed by an upper GI 
series. Standard commercial formulas, Peptamen and Compleat B (Clintec 
Nutrition, Deerfield, lll), are used for enteral nutrition, starting with a di-
luted solution at a low infusion rate. Nutrition via the parenteral route is 
gradually tapered in conjunction with a reciprocal increase of enteric nutri-
tion by tube feeding and oral intake. Supplementary administration of in-
travenous fluids is mandatory to compensate for postoperative fluid loss 
through the stomal output and diarrhea. 
Assessment of Intestinal Graft function 
Clinically, assessment of intestinal graft function is accomplished by study-
ing TPN dependency, weight, height (in pediatrics), volume of stomal out-
put, and frequency and nature of the stool. In addition, studies are con-
ducted periodically to determine absorptive, secretory, and motility func-
tion of the graft. Absorptive function is examined by the o-xylose absorp-
tion test, 72-hour fecal fat secretion, FK506 pharmacokinetics, Schilling 
test, and serum levels of vitamins, protein, and minerals. Measurement of 
serum IgA levels reflects secretory activity of the intestine. Gastrointestinal 
motility and transit are studied by radionuclear scanning after test meal in-
gestion, manometry, and conventional barium studies. 
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Results 
Case Material 
Table 3 summarizes demographics of the 30 recipients who were treated 
by intestinal transplantation at our center from May 1990 to November 
1992. Fifteen were children with a mean age of 2.7 years, and the other 
15 were adults wlth a mean age of 29.8 years. All of the patients had been 
managed by TPN for 1 to 132 months and had experienced more than 
one episode of TPN-related complications, in which liver failure with mean 
bilirubin of 18.2 mgldL, ranging from 2.3 mgldL to 50.5 mg/dL, was seen 
in 19 patients. Twenty-seven patients had surgical intestinal failure, and 
functional disorder was the indication for transplantation in the remaining 3 
patients. Nine patients received an isolated graft, 17 had combined grafts, 
and 4 received multivisceral grafts. 
Postoperative Course 
Postoperatively, patients were managed in the intensive care unit (lCU) in 
the same manner as liver recipients for ventilatory support, fluid and elec-
trolyte management, and intensive immunosuppressive therapy. Isolated 
intestinal recipients recovered faster after transplantation and were dis-
charged from the ICU earlier, 6 days vs. 12 days, than those receiving 
combined or multivisceral grafts because of less operative complexity and 
better preoperative conditions. Initiation of enteral feeding and discontinu-
ation of TPN were also much faster with isolated intestinal recipients, 9 
days vs. 18.5 days, and 30 days vs. 48 days, probably for the same rea-
sons. 
Survival 
Twenty-four of the 30 recipients (80%) are currently alive for 4 to 32 
months after intestinal transplantation. Survival rates for patients receiving 
an isolated graft, combined grafts, and multivisceral grafts were 78% (7/9), 
76% (13/17), and 100% (4/4), respectively. 
Of the nine isolated graft recipients, three patients required graft removal 
due to acute (n = 2) or drug-noncompliant chronic (n = 1) rejection, for 
which one patient underwent retransplantation and died. Graft survival 
was 60% (6/10). Graft survival rates for combined and multivisceral grafts 
were the same as those of the patients. 
Mortality 
Of the six deaths, three patients died within 3 months after transplantation 
and the remaining 3 died after 1 year. The early deaths were children re-
ceiving combined grafts. Sepsis related to technical failure (intestinal anas-
tomotic leakage, biliary leakage, or hepatic artery thrombosis) was the 
cause of mortality in all of these early deaths. Of the three late mortalities, 
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one child who received a combined small bowel-liver graft died of lym-
phoproliferative disease at 13 months. Two adult patients who underwent 
isolated graft transplantation died, at 12 months from sepsis after graft re-
moval for acute rejection, and at 26 months, also from sepsis after intesti-
nal retransplantation. 
Rejection 
The overall incidence of acute intestinal rejection was 87.5%. The risk of 
rejection was high at 75% within 1 month, reduced to 20% at the third 
month, but increased again after 6 months mostly due to transient reduc-
tion of immunosuppression for viral or fungal infection. Chronic rejection 
was demonstrated histologically in two failed grafts. One graft was re-
moved at 21 months for drug-noncompliant rejection, and the other was 
removed at 8 months due to rejection induced by withdrawal of immuno-
suppression for demyelination of the white matter of the brain. 
Graft-vs.-host disease has been a threat in intestinal transplantation, but 
has actually occurred in only one patient (0.03%) in our series (1130). The 
patient developed pneumocystis pneumonia and intestinal anastomotic 
leakage within a week after combined grafting, which compelled a marked 
reduction in immunosuppression. Graft-vs.-host disease was diagnosed by 
immunohistologic study of skin biopsies which were taken a day before the 
patient died, but was not seen in the skin biopsies taken 4 days previously. 
Cellular or humoral evidence of GVH disease after intestinal transflanta-
tion was described in only three patients among past clinical cases. ,10, 12 
Infection 
All but two adult patients developed bacterial infection postoperatively. 
Line sepsis, abdominal wound infection, and peritonitis are major sources 
of infection. Bacterial translocation was seen in each of two adult and pe-
diatric recipients, and successfully treated by augmentation of immunosup-
pression and antibiotics. Seven of the 15 adult recipients developed CMV 
enteritis 1 to 4 months after transplantation, of which 2 had persistent in-
fection. Three of the 15 pediatric recipients developed postoperative Iym-
phoproliferative disease by Epstein-Barr virus infection, and one had a le-
thal outcome. 
Graft Function 
Stomal discharge, reflecting resumption of gastrointestinal motility, was 
seen within 2 to 3 days after transplantation, progressively increased to 1 
to 2 Uday, and then became stable at 0.5 to 1.0 Uday after 3 to 6 
months. Dysmotility developed postoperatively on both native stomach 
and transplanted intestine. Delayed gastric emptying was detected by 
barium study and radioisotope scanning in 75% of the patients within the 
first 2 months. It resolved spontaneously to 30% at 4 months and 15 % by 
6 months. The cause of delayed gastric emptying is unclear. More than 
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one half of the recipients had accelerated small-intestine transit time of less 
than 2 hours by barium study, and a few patients showed prolonged tran-
sit time of more than 4 hours. Both abnormalities subsided spontaneously 
in a majority of the recipients in 6 to 12 months. All but one of the 23 
surviving patients with functioning grafts are completely free from TPN 
(see Table 3). All of them have gained or maintained body weight solely 
by enteral nutrition. One recipient requires partial TPN support during the 
night because of very high stomal output. Serum protein and albumin lev-
els of the patients are within normal ranges with satisfactory absorption of 
FK506 and o-xylose, but 72-hour fecal fat secretions are abnormal in all of 
the patients, ranging from 2.4% to 88.3%. 
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